Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -321.81% is 48% above its 5-year average of -614.88%, near the high end of its 5-year range (-6391.57%–0.00%).
6.20% below its 12-month average of -303.03%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -214.01%.
NET PROFIT MARGIN
-321.81%
NET PROFIT MARGIN AVG TTM
-303.03%
NET PROFIT MARGIN AVG 3Y
-336.22%
NET PROFIT MARGIN AVG 5Y
-614.88%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-6.20%
CURRENT VS 3Y AVG
+4.29%
CURRENT VS 5Y AVG
+47.66%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-123673.08%
vs the sector median at left
Janux Therapeutics, Inc.
Market Cap
$1.02B
Net Profit Margin
-321.81%
TTM Avg
-303.03%
3Y Avg
-336.22%
5Y Avg
-614.88%
Market Cap
$1.02B
Net Profit Margin
-2.66%
TTM Avg
-7.26%
3Y Avg
-9.19%
5Y Avg
-9.19%
Market Cap
$1.02B
Net Profit Margin
-5.43%
TTM Avg
-0.76%
3Y Avg
-19.17%
5Y Avg
-21.06%
Market Cap
$1.03B
Net Profit Margin
-0.44%
TTM Avg
-16.00%
3Y Avg
-4.01%
5Y Avg
0.78%
Market Cap
$1.01B
Net Profit Margin
-493.26%
TTM Avg
-198.62%
3Y Avg
-139.13%
5Y Avg
-250.17%
Market Cap
$1.01B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-57.69%
Market Cap
$996.21M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$993.61M
Net Profit Margin
-32.54%
TTM Avg
-35.87%
3Y Avg
-66.42%
5Y Avg
-187.72%
Market Cap
$991.32M
Net Profit Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | $1.02B | -321.81% | -303.03% | -336.22% | -614.88% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | -2.66% | -7.26% | -9.19% | -9.19% |
| Castle Biosciences, Inc. (CSTL)vs › | $1.02B | -5.43% | -0.76% | -19.17% | -21.06% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | -0.44% | -16.00% | -4.01% | 0.78% |
| Immatics N.V. (IMTX)vs › | $1.01B | -493.26% | -198.62% | -139.13% | -250.17% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | 0.00% | 0.00% | 0.00% | -57.69% |
| Vor Biopharma Inc. (VOR)vs › | $996.21M | 0.00% | 0.00% | 0.00% | 0.00% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $993.61M | -32.54% | -35.87% | -66.42% | -187.72% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $991.32M | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.06B | -7.13% | -23.45% | -155.72% | -114.72% |
Operating Margin
-1576.7%
Net Profit Margin
-321.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -214.01% |
| 2026-03-31 | -652.59% |
| 2025-12-31 | -405.41% |
| 2025-09-30 | -243.13% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | -6391.57% |
| 2024-06-30 | -66.98% |
| 2024-03-31 | -1178.91% |
| 2023-12-31 | -477.77% |
| 2023-09-30 | -459.59% |
| 2023-06-30 | -1656.39% |
| 2023-03-31 | -852.49% |
| 2022-12-31 | -564.67% |
| 2022-09-30 | -920.90% |
| 2022-06-30 | -714.08% |
| 2022-03-31 | -843.93% |
| 2021-12-31 | -830.20% |
| 2021-09-30 | -928.90% |
| 2021-06-30 | -1287.55% |
| 2021-03-31 | -601.05% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
